Methotrexate Sodium Injectio · #26 of 35 active shortages by FDA posting duration
Brand: METHOTREXATE
FDA lists Methotrexate Sodium Injectio as Active Shortage (Teva Pharmaceuticals USA, Inc.).
Availability on file: Limited Availability
Methotrexate Sodium Injection: Active Shortage
Limited Availability 21 shortage presentations are tracked for this drug. Contact your pharmacist if you are affected.
Shortage Details
- Generic Name
- Methotrexate Sodium Injection
- Manufacturer
- Teva Pharmaceuticals USA, Inc.
- Dosage Form
- Injection
- Presentation
- Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01)
- Package NDC
- 0703-3675-01
Status & Timeline
- Status
- Active Shortage
- Availability
- Limited Availability
- First Reported
- Mar 13, 2023
- Last Updated
- Mar 16, 2026
- Therapeutic Category
- Rheumatology, Oncology
Row fields from the FDA Drug Shortages database via openFDA.
Shortage Reason
Estimated recovery: January 2027
Full Drug Profile
methotrexate
Side effects, interactions, warnings & more
Nearby, Other Methotrexate Shortage Records
Methotrexate Sodium Injection
Fresenius Kabi USA, LLC
Injection
Methotrexate Sodium Injection
Fresenius Kabi USA, LLC
Injection
Methotrexate Sodium Injection
Accord Healthcare Inc.
Injection
Methotrexate Sodium Injection
Accord Healthcare Inc.
Injection
Methotrexate Sodium Injection
Teva Pharmaceuticals USA, Inc.
Injection
Methotrexate Sodium Injection
Teva Pharmaceuticals USA, Inc.
Injection
FDA reason on file: Estimated recovery: January 2027. General shortage guidance lives on the tracker hub.